The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths.
Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies…

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. …

Antibody responses develop following SARS-CoV-2 infection, but little is known about their
epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We …

Broadly neutralizing antibodies (bnAbs) against HIV are believed to be a critical component
of the protective responses elicited by an effective HIV vaccine. Neutralizing antibodies …

While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two
doses administered 3 weeks apart, some public health authorities are spacing these doses, …

SARS-CoV-2 is a betacoronavirus virus responsible for the COVID-19 pandemic. Here, we
determine the X-ray crystal structure of a potent neutralizing monoclonal antibody, CV30, …

A subset of individuals infected with HIV-1 develops broadly neutralizing antibodies (bNAbs)
that can prevent infection, but it has not yet been possible to elicit these antibodies by …

Neutralizing antibodies (NAbs) are effective in treating COVID-19, but the mechanism of
immune protection is not fully understood. Here, we applied live bioluminescence imaging (BLI) …

Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of
antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector …